Stephane Van Rooijen
Stephane Van Rooijen is chief executive officer of Flamingo Therapeutics and is based in Leuven. He took up the role in March 2023, holding it until December 2025, and since 2024 has also volunteered as a mentor with the Termeer Institute.
Before joining Flamingo Therapeutics, he was chief executive officer of Dynacure from 2016 to 2023 and of Confo Therapeutics from 2014 to 2016. Between 2012 and 2014 he was a director at ViroPharma Incorporated, which was acquired by Shire in 2014. He spent 2005 to 2012 at Genzyme, a Sanofi Division, first as director of commercial development and finance and then as senior director for cardiovascular Europe within the rare diseases division. Earlier, he was a manager at Arthur D. Little from 1996 to 2004, and practised medicine from 1994 to 1996.
He holds a Doctor of Medicine from KU Leuven and a full-time MBA from Erasmus University Rotterdam, with an exchange MBA at Georgetown University McDonough School of Business.
Career
Roles
- Termeer InstituteMentor - volunteering2024 – Present
Flamingo TherapeuticsChief Executive OfficerMar 2023 – Dec 2025
- DynacureChief Executive Officer (Dynacure merged with Flamingo Therapeutics in 2023)2016 – 2023
Confo TherapeuticsChief Executive Officer2014 – 2016
- ViroPharma Incorporated - acquired by Shire in 2014Director2012 – 2014
- Genzyme, a Sanofi DivisionSenior Director Cardiovascular Europe - Rare Diseases Division2006 – 2012
- Genzyme, a Sanofi DivisionDirector Commercial Development and Finance2005 – 2006
- Arthur D. Little#169factoryManager1996 – 2004
- MDMedical practice1994 – 1996
Education
Erasmus University Rotterdam#82schoolMaster of Business Administration (MBA, full-time)
- Georgetown University McDonough School of BusinessMBA - exchange
KU Leuven#1schoolDoctor of Medicine (M.D.)
From public career histories · 12 entries